JP2021522211A5 - - Google Patents
Info
- Publication number
- JP2021522211A5 JP2021522211A5 JP2020558435A JP2020558435A JP2021522211A5 JP 2021522211 A5 JP2021522211 A5 JP 2021522211A5 JP 2020558435 A JP2020558435 A JP 2020558435A JP 2020558435 A JP2020558435 A JP 2020558435A JP 2021522211 A5 JP2021522211 A5 JP 2021522211A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- carbon atoms
- alkoxy
- halo
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023167782A JP2023165946A (ja) | 2018-04-16 | 2023-09-28 | Ｅｐ４阻害剤およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862658494P | 2018-04-16 | 2018-04-16 | |
| US62/658,494 | 2018-04-16 | ||
| US201862737219P | 2018-09-27 | 2018-09-27 | |
| US62/737,219 | 2018-09-27 | ||
| PCT/US2019/027603 WO2019204257A1 (en) | 2018-04-16 | 2019-04-16 | Ep4 inhibitors and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023167782A Division JP2023165946A (ja) | 2018-04-16 | 2023-09-28 | Ｅｐ４阻害剤およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522211A JP2021522211A (ja) | 2021-08-30 |
| JP2021522211A5 true JP2021522211A5 (https=) | 2022-04-25 |
| JPWO2019204257A5 JPWO2019204257A5 (https=) | 2022-04-25 |
Family
ID=66589884
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020558435A Pending JP2021522211A (ja) | 2018-04-16 | 2019-04-16 | Ｅｐ４阻害剤およびその使用 |
| JP2023167782A Pending JP2023165946A (ja) | 2018-04-16 | 2023-09-28 | Ｅｐ４阻害剤およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023167782A Pending JP2023165946A (ja) | 2018-04-16 | 2023-09-28 | Ｅｐ４阻害剤およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10973834B2 (https=) |
| EP (1) | EP3781162A1 (https=) |
| JP (2) | JP2021522211A (https=) |
| CN (1) | CN112292128A (https=) |
| AU (1) | AU2019255196A1 (https=) |
| CA (1) | CA3096546A1 (https=) |
| WO (1) | WO2019204257A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10973834B2 (en) | 2018-04-16 | 2021-04-13 | Arrys Therapeutics, Inc. | EP4 inhibitors and use thereof |
| US20210315909A1 (en) | 2018-07-11 | 2021-10-14 | Arrys Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| JP7640458B2 (ja) | 2018-10-05 | 2025-03-05 | アンナプルナ バイオ インコーポレイテッド | Ａｐｊ受容体活性に関連する状態を処置するための化合物および組成物 |
| EP3722319A1 (en) * | 2019-04-09 | 2020-10-14 | Rottapharm Biotech S.r.l. | Pharmaceutical combination of an ep4 antagonist and immune checkpoint inhibitors for the treatment of tumours |
| CN110386941A (zh) * | 2019-08-15 | 2019-10-29 | 上海邦耀生物科技有限公司 | Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗 |
| CN115697317A (zh) * | 2020-04-08 | 2023-02-03 | 株式会社AskAt | Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用 |
| WO2021226162A1 (en) * | 2020-05-05 | 2021-11-11 | Arrys Therapeutics, Inc. | Ep4 antagonists and their use in the treatment of proliferative diseases |
| US11857551B1 (en) | 2020-07-10 | 2024-01-02 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
| EP4215214A4 (en) * | 2020-09-16 | 2024-07-03 | Osaka University | THERAPEUTIC AGENT AGAINST CANCER, IMMUNOSTIMULANT AND SCREENING METHOD FOR ANTI-CANCER SUBSTANCE |
| CN114907267A (zh) * | 2021-02-08 | 2022-08-16 | 中国科学院上海药物研究所 | 用于抗肿瘤的药物组合 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| CN1867551B (zh) | 2003-09-03 | 2013-09-11 | 拉夸里亚创药株式会社 | 作为前列腺素e2拮抗剂的苯基或吡啶基酰胺化合物 |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| CN101137656B (zh) | 2005-03-11 | 2010-12-22 | 拉夸里亚创药株式会社 | 咪唑衍生物的晶型 |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CA2634198C (en) | 2005-12-20 | 2014-06-03 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| ES2444574T3 (es) | 2006-09-19 | 2014-02-25 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| JP5583592B2 (ja) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | Ｉｄｏ阻害剤 |
| US20110176972A1 (en) | 2008-05-29 | 2011-07-21 | Saint-Gobain Centre De Recherches et D'Etudes Eur | Cellular structure containing aluminium titanate |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| EP3431085B1 (en) | 2009-04-22 | 2023-10-11 | AskAt Inc. | Selective ep4 receptor antagonistic substance for treatment of cancer |
| JP5594754B2 (ja) | 2009-07-13 | 2014-09-24 | 国立大学法人 東京大学 | 運行実績を活用したオンデマンドバスの運行スケジューリングシステム及びその方法 |
| EP2473531A4 (en) | 2009-09-03 | 2013-05-01 | Merck Sharp & Dohme | Anti-gitr antibodies |
| US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| PH12012500881A1 (en) | 2009-12-10 | 2017-07-26 | Hoffmann La Roche | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| ES2600355T3 (es) | 2010-02-22 | 2017-02-08 | Raqualia Pharma Inc. | Uso de un antagonista del receptor EP4 en el tratamiento de dermatitis de contacto alérgica y psoriasis |
| JP5998060B2 (ja) | 2010-03-04 | 2016-09-28 | マクロジェニクス，インコーポレーテッド | Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| MX378336B (es) | 2010-05-04 | 2025-03-10 | Five Prime Therapeutics Inc | Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r). |
| PT2614082T (pt) | 2010-09-09 | 2018-12-03 | Pfizer | Moléculas de ligação a 4-1bb |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| US20150004175A1 (en) * | 2011-12-13 | 2015-01-01 | Yale University | Compositions and Methods for Reducing CTL Exhaustion |
| BR112014012624A2 (pt) | 2011-12-15 | 2018-10-09 | F Hoffmann-La Roche Ag | anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo |
| RU2014136332A (ru) | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | Композиции и способы применения ингибиторов csf1r |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| EP2847220A1 (en) | 2012-05-11 | 2015-03-18 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| CN107496421A (zh) | 2013-03-19 | 2017-12-22 | 株式会社ＡｓｋＡｔ | Ep4受体拮抗剂在软骨疾病的治疗中的用途 |
| US10391086B2 (en) | 2013-03-19 | 2019-08-27 | Askat Inc. | Use of EP4 receptor antagonists in the treatment of cartilage disease |
| NZ733234A (en) | 2014-03-06 | 2018-08-31 | Aratana Therapeutics Inc | Crystalline forms of grapiprant |
| KR102535283B1 (ko) * | 2014-05-23 | 2023-05-22 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 암의 치료를 위한 조합 요법 |
| UY36390A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| HUE057799T2 (hu) * | 2016-07-07 | 2022-06-28 | Ono Pharmaceutical Co | EP4 antagonistát és immunellenõrzõpont gátlót tartalmazó kombináció |
| US10342785B2 (en) * | 2016-11-04 | 2019-07-09 | Askat Inc. | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
| US20190365680A1 (en) | 2016-11-04 | 2019-12-05 | Askat Inc. | Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer |
| US10973834B2 (en) * | 2018-04-16 | 2021-04-13 | Arrys Therapeutics, Inc. | EP4 inhibitors and use thereof |
| US20210315909A1 (en) | 2018-07-11 | 2021-10-14 | Arrys Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| EP3820469A4 (en) | 2018-07-11 | 2022-04-13 | Arrys Therapeutics, Inc. | EP4 INHIBITORS AND SYNTHESIS THEREOF |
| CN113260363A (zh) | 2018-09-27 | 2021-08-13 | 阿瑞斯医疗有限公司 | 格拉普兰特(grapiprant)单位剂型 |
| CN115697317A (zh) * | 2020-04-08 | 2023-02-03 | 株式会社AskAt | Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用 |
-
2019
- 2019-04-16 US US16/385,524 patent/US10973834B2/en active Active
- 2019-04-16 WO PCT/US2019/027603 patent/WO2019204257A1/en not_active Ceased
- 2019-04-16 JP JP2020558435A patent/JP2021522211A/ja active Pending
- 2019-04-16 CA CA3096546A patent/CA3096546A1/en active Pending
- 2019-04-16 AU AU2019255196A patent/AU2019255196A1/en not_active Abandoned
- 2019-04-16 CN CN201980033839.6A patent/CN112292128A/zh active Pending
- 2019-04-16 EP EP19724972.5A patent/EP3781162A1/en not_active Withdrawn
-
2021
- 2021-03-01 US US17/187,900 patent/US20210290641A1/en not_active Abandoned
-
2023
- 2023-07-19 US US18/355,232 patent/US20240066040A1/en not_active Abandoned
- 2023-09-28 JP JP2023167782A patent/JP2023165946A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021522211A5 (https=) | ||
| Kwapisz | Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib | |
| Jhaveri et al. | A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer | |
| RU2597844C2 (ru) | Введение гипоксически активируемых пролекарств и средств, препятствующих ангиогенезу, для лечения рака | |
| Konings et al. | The applicability of mTOR inhibition in solid tumors | |
| O’Sullivan | Overcoming endocrine resistance in hormone-receptor positive advanced breast cancer-the emerging role of CDK4/6 inhibitors | |
| EP2882454B1 (en) | Combination therapy for the treatment of glioblastoma | |
| JP2015532292A5 (https=) | ||
| Polk et al. | Specific CDK4/6 inhibition in breast cancer: a systematic review of current clinical evidence | |
| Leung et al. | Potentiation of growth inhibitory responses of the mTOR inhibitor everolimus by dual mTORC1/2 inhibitors in cultured breast cancer cell lines | |
| RU2018111439A (ru) | Новое пиразоло[3, 4-d]пиримидиновое соединение или его соль | |
| MX2014011925A (es) | Dosificacion y administracion de anticuerpos monoespecíficos y biespecíficos anti- igf 1r y anti erbb3. | |
| MX2011000440A (es) | Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek. | |
| KR102082363B1 (ko) | 난소암의 치료를 위한 조합 치료 | |
| JP2013531069A (ja) | ４−ヨード−３−ニトロベンズアミド及びイリノテカンを用いる転移性乳癌の治療方法 | |
| JP2011121944A5 (https=) | ||
| WO2013138371A1 (en) | Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody | |
| JP2014533277A5 (https=) | ||
| TN2012000493A1 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations | |
| US20160303232A1 (en) | Combination treatments with seribantumab | |
| JPWO2019204257A5 (https=) | ||
| Martino et al. | Selinexor in multiple myeloma | |
| L Hixon et al. | Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway | |
| Arena et al. | Stomatitis and everolimus: a review of current literature on 8,201 patients | |
| Juengel et al. | Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells |